View in EDS HTML Full Text PDF Full Text

Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial.

Saved in:
Bibliographic Details
Title: Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial.
Authors: Hamilton EP; Sarah Cannon Research Institute, 250 25th Avenue North, Nashville, TN, 37203, USA. Erika.Hamilton@scri.com., Falchook GS; Sarah Cannon Research Institute at HealthONE, Denver, CO, USA., Wang JS; Sarah Cannon Research Institute, 250 25th Avenue North, Nashville, TN, 37203, USA.; Florida Cancer Specialists, Sarasota, FL, USA., Fu S; MD Anderson Cancer Center, Houston, TX, USA., Oza AM; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada., Imedio ER; Oncology R&D, AstraZeneca, Cambridge, UK., Kumar S; Oncology R&D, AstraZeneca, Cambridge, UK., Ottesen L; Oncology R&D, AstraZeneca, Cambridge, UK., Mugundu GM; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Boston, MA, USA., de Bruin EC; Oncology R&D, AstraZeneca, Cambridge, UK., O'Connor MJ; Oncology R&D, AstraZeneca, Cambridge, UK., Jones SF; Sarah Cannon Research Institute, 250 25th Avenue North, Nashville, TN, 37203, USA., Spigel DR; Sarah Cannon Research Institute, 250 25th Avenue North, Nashville, TN, 37203, USA., Li BT; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Source: Targeted oncology [Target Oncol] 2024 Nov; Vol. 19 (6), pp. 879-892. Date of Electronic Publication: 2024 Nov 01.
Publication Type: Journal Article; Clinical Trial, Phase I; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39487373
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Hamilton+EP%22">Hamilton EP</searchLink>; Sarah Cannon Research Institute, 250 25th Avenue North, Nashville, TN, 37203, USA. Erika.Hamilton@scri.com.<br /><searchLink fieldCode="AU" term="%22Falchook+GS%22">Falchook GS</searchLink>; Sarah Cannon Research Institute at HealthONE, Denver, CO, USA.<br /><searchLink fieldCode="AU" term="%22Wang+JS%22">Wang JS</searchLink>; Sarah Cannon Research Institute, 250 25th Avenue North, Nashville, TN, 37203, USA.; Florida Cancer Specialists, Sarasota, FL, USA.<br /><searchLink fieldCode="AU" term="%22Fu+S%22">Fu S</searchLink>; MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Oza+AM%22">Oza AM</searchLink>; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada.<br /><searchLink fieldCode="AU" term="%22Imedio+ER%22">Imedio ER</searchLink>; Oncology R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Kumar+S%22">Kumar S</searchLink>; Oncology R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Ottesen+L%22">Ottesen L</searchLink>; Oncology R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Mugundu+GM%22">Mugundu GM</searchLink>; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22de+Bruin+EC%22">de Bruin EC</searchLink>; Oncology R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22O'Connor+MJ%22">O'Connor MJ</searchLink>; Oncology R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Jones+SF%22">Jones SF</searchLink>; Sarah Cannon Research Institute, 250 25th Avenue North, Nashville, TN, 37203, USA.<br /><searchLink fieldCode="AU" term="%22Spigel+DR%22">Spigel DR</searchLink>; Sarah Cannon Research Institute, 250 25th Avenue North, Nashville, TN, 37203, USA.<br /><searchLink fieldCode="AU" term="%22Li+BT%22">Li BT</searchLink>; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101270595%22">Targeted oncology</searchLink> [Target Oncol] 2024 Nov; Vol. 19 (6), pp. 879-892. <i>Date of Electronic Publication: </i>2024 Nov 01.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I; Multicenter Study; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer-Verlag+France%22">Springer-Verlag France </searchLink><i>Country of Publication: </i>France <i>NLM ID: </i>101270595 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1776-260X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2217762596%22">17762596 </searchLink><i>NLM ISO Abbreviation: </i>Target Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39487373
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s11523-024-01102-8
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 879
    Titles:
      – TitleFull: Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Hamilton EP
      – PersonEntity:
          Name:
            NameFull: Falchook GS
      – PersonEntity:
          Name:
            NameFull: Wang JS
      – PersonEntity:
          Name:
            NameFull: Fu S
      – PersonEntity:
          Name:
            NameFull: Oza AM
      – PersonEntity:
          Name:
            NameFull: Imedio ER
      – PersonEntity:
          Name:
            NameFull: Kumar S
      – PersonEntity:
          Name:
            NameFull: Ottesen L
      – PersonEntity:
          Name:
            NameFull: Mugundu GM
      – PersonEntity:
          Name:
            NameFull: de Bruin EC
      – PersonEntity:
          Name:
            NameFull: O'Connor MJ
      – PersonEntity:
          Name:
            NameFull: Jones SF
      – PersonEntity:
          Name:
            NameFull: Spigel DR
      – PersonEntity:
          Name:
            NameFull: Li BT
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: 2024 Nov
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1776-260X
          Numbering:
            – Type: volume
              Value: 19
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Targeted oncology
              Type: main
ResultId 1